48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
To address the preventive & primary healthcare delivery gaps in India
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
India has the second-largest number of adults with diabetes globally, after China
Jamnagar’s contributions towards wellness will get a global identity with WHO’s Global Centre for Traditional Medicine
Dr. Muffazal Lakdawala performs the largest series of complete robotic gastric bypass surgery in India
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The drug is priced at Rs 2000 for a course of 40 tablets
Subscribe To Our Newsletter & Stay Updated
